(Q36544712)

14 August 2017

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis (English)

1 reference

14 August 2017

1 reference

1

Yair Lotan

1 reference

14 August 2017

Robert S Svatek

2

1 reference

PubMed ID

16862567

14 August 2017

Arthur I Sagalowsky

series ordinal

3

1 reference

PubMed ID

16862567

14 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

14 August 2017

1 reference

14 August 2017

107

1 reference

14 August 2017

982-990

1 reference

14 August 2017

5

1 reference

The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group

14 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

The health economics of bladder cancer: a comprehensive review of the published literature.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

A community study of bladder cancer screening by the detection of occult urinary bleeding.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Detection of bladder cancer using a point-of-care proteomic assay

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Superficial bladder cancer: progression and recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Factors affecting recurrence and progression in superficial bladder tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Standardizing cost-effectiveness analyses: the panel on cost-effectiveness in health and medicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Controversies in prostate cancer screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Screening and monitoring for bladder cancer: refining the use of NMP22

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

A quantitative analysis of the costs and benefits of prostate cancer screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

The cervical cancer epidemic that screening has prevented in the UK.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22084

7 January 2021

Identifiers

DOI

10.1002/CNCR.22084

1 reference

14 August 2017

1 reference

PubMed ID

16862567